decibel therapeutics hearing loss prevention

Decibel Therapeutics to Present New Findings at American Society of Gene & Cell Therapy Meeting

BOSTON, MASSACHUSETTS – Decibel Therapeutics, a clinical-stage biotechnology company developing novel gene therapeutics for restoration of hearing loss and balance disorders, today announced that it will present new findings on its pipeline and platform at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), which will be held virtually from May 12–15. Decibel’s…

Read More
decibel therapeutics hearing loss prevention

Decibel Therapeutics Publishes Encouraging Results from Phase 1a Clinical Trial of DB-020

BOSTON, MASSACHUSSETTS — Decibel Therapeutics, a development-stage biotechnology company developing novel regenerative therapeutics for hearing loss and balance disorders, announced that Phase 1a trial results demonstrating the safety and tolerability of its lead candidate, DB-020, have been published in the peer-reviewed journal Investigational New Drugs. DB-020 is being developed for the prevention of cisplatin-induced hearing…

Read More
decibel therapeutics hearing loss

Decibel Therapeutics Appoints New CEO; Announces Strategic Research Focus on Regenerative Medicine for Inner Ear

BOSTON, MASSACHUSSETTS — Biotech startup, Decibel Therapeutics, announced today that the company has appointed Laurence Reid, Ph.D., as acting chief executive officer, bringing extensive experience in biotech company building. According to the company announcement, CEO Steven Holtzman is retiring and will become a strategic business advisor to the company. As CEO, Dr. Reid brings experience in…

Read More
decibel therapeutics

Healthcare Industry Veteran, Christine Poon, Appointed to Decibel Therapeutics Board of Directors

BOSTON, MASSACHUSETTS — Biotech startup, Decibel Therapeutics, has announced the appointment of Christine Poon to its board of directors. Ms. Poon has spent more than 30 years in leadership roles in the biopharmaceutical industry. She currently serves as executive in residence of The Max M. Fisher College of Business at The Ohio State University, having…

Read More
decibel therapeutics

Decibel Therapeutics Appoints New Chief Medical Officer and COO

BOSTON, MASSACHUSETTS — Biotech startup, Decibel Therapeutics, has announced the appointment of Dr. Peter Weber as the company’s new Chief Medical Officer, as well as the promotion of Paula Cobb to Chief Operating Officer. Dr. Weber, an otolaryngologist at Boston University Medical Center specializing in otology/neurotology, brings experience as a clinician, a scientist and a hearing…

Read More
decibel therapeutics

Pharmaceutical Treatments for Hearing Loss, a Brief Q&A with Michael Su, Ph.D., CSO of Decibel Therapeutics

Hearing loss is a critical public health issue that carries a significant social and economic cost. Decibel Therapeutics, a biotechnology startup based in Boston, is pursuing a comprehensive approach to developing precision medications for hearing and balance. We talked with Decibel’s chief scientific officer, Michael Su, Ph.D., about that work. Su and his colleagues will…

Read More
decibel partnership cocoon

Decibel Therapeutics and Cocoon Biotech Announce Research Collaboration

BOSTON, MASSACHUSETTS — Biotech startup, Decibel Therapeutics, has announced a research collaboration with Cocoon Biotech to apply Cocoon’s proprietary silk fibroin platform to the development of therapeutics for hearing and balance disorders. According to the announcement, the companies will jointly conduct research into drug formulations optimized for transtympanic delivery to the ear, and Decibel will…

Read More
decibel therapeutics hearing loss drug license oricula

Decibel Therapeutics Obtains Exclusive License to Develop and Commercialize ORC-13661 from Oricula Therapeutics

BOSTON & SEATTLE — Boston-based biotech firm, Decibel Therapeutics, announced this week that it has obtained “an exclusive, worldwide license to the development and commercialization of ORC-13661” from Oricula Therapeutics for the prevention of hearing loss and balance disorders due to the use of aminoglycoside antibiotics. As part of the agreement with Decibel, Oricula will…

Read More
decibel hearing loss drug financing

Decibel Therapeutics Snags $55 Million Series C Financing for Hearing Drug Development

BOSTON, MASSACHUSETTS — Biotech startup, Decibel Therapeutics, announced that it has raised $55M in a Series C financing round. According to the announcement, all the existing investors–Third rock Ventures, GV, SR One and Regeneron Pharmaceuticals–participated in the financing round and were joined alongside new investors: Foresite Capital, Bessemer Trust, Schroder Adveq, SCubed Capital, Longevity, and…

Read More
hearing loss drug development

Sound Pharmaceuticals Completes Clinical Trial Enrollment on Meniere’s Drug; GV Invests in Decibel Therapeutics

SEATTLE, WASHINGTON — Sound Pharmaceuticals, a Seattle-based biotech firm, announced late last month that it had completed enrollment on its first Ménière’s disease clinical trial. The clinical trial will use SPI-1005, an investigational new drug developed by the company that mimics and induces Glutathione Peroxidase (GPx), which has been shown to reduce the swelling or…

Read More